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Abstract
Background: The Hedgehog (HH) signalling pathway regulates cardiomyogenesis in vivo and in differentiating P19
embryonal carcinoma (EC) cells, a mouse embryonic stem (mES) cell model. To further assess the transcriptional
role of HH signalling during cardiomyogenesis in stem cells, we studied the effects of overexpressing GLI2, a
primary transducer of the HH signalling pathway, in mES cells.
Results: Stable GLI2 overexpression resulted in an enhancement of cardiac progenitor-enriched genes, Mef2c, Nkx2-
5, and Tbx5 during mES cell differentiation. In contrast, pharmacological blockade of the HH pathway in mES cells
resulted in lower expression of these genes. Mass spectrometric analysis identified the chromatin remodelling factor
BRG1 as a protein which co-immunoprecipitates with GLI2 in differentiating mES cells. We then determined that
BRG1 is recruited to a GLI2-specific Mef2c gene element in a HH signalling-dependent manner during
cardiomyogenesis in P19 EC cells, a mES cell model.
Conclusions: Thus, we propose a mechanism where HH/GLI2 regulates the expression of Mef2c by recruiting BRG1
to the Mef2c gene, most probably via chromatin remodelling, to ultimately regulate in vitro cardiomyogenesis.
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Background
The embryonic heart is the first organ to develop and is
essential for life. Perturbations in heart development can
lead to congenital heart disease, which is the most com-
mon birth defect in the Western world [1]. During heart
development, cardiac precursors populate the first and
the second heart fields (FHF and SHF), which establish
the cardiac crescent by embryonic day (E) 7.5 [2, 3]. In
the cardiac crescent a transcriptional network regulates
cardiac progenitor differentiation in a spatiotemporal
manner through a crosstalk of inductive signals from
surrounding tissues, including hedgehog (HH) [4, 5].
These signals lead to the expression of cardiac progenitor-
enriched transcription factors, including NK2 homeobox
5 protein (NKX2-5), myocyte-specific enhancer factor 2C
(MEF2C), T-box protein 5 (TBX5), and GATA-binding
protein 4 (GATA-4), which are essential for efficient heart
looping and morphogenesis [5–10].
When one of the three mammalian HH ligands - Indian
(IHH), desert (DHH), or sonic hedgehog (SHH) - binds
to and inhibits the transmembrane protein, patched 1
(PTCH1) [11, 12], smoothened (SMO) initiates the
transition of glioma-associated (GLI) proteins into the
nucleus for modulation of HH target gene expression
[13]. GLI2 is a primary transducer and activator of the
response to HH signalling [13]. GLI1 is a transcrip-
tional activator but its expression is dependent on GLI2
and/or GLI3 [13]. In the absence of HH ligand, PTCH1
inhibits SMO activity, which triggers phosphorylation of
the GLI proteins and results in their proteolytic cleavage
and/or degradation [14]. While phosphorylation of GLI3
mostly yields a partially cleaved GLI3 transcriptional re-
pressor (GLI3R), which represses the expression of HH
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target genes, the phosphorylation of GLI2 mainly leads to
its complete proteasomal degradation [13].
Shh-/- mice have altered heart looping [15] and a single
outflow tract [16]. Mice with tissue specific knockout of
Shh-/- in the SHF, using Nkx2-5-Cre, display outflow
tract septation defects [17]. Shh-/-/Ihh-/- or Smo-/- em-
bryos have a delayed Nkx2-5 expression and heart tube
formation [18]. In accordance, Ptch1-/- embryos, which
have the negative regulation of HH signalling removed,
express higher levels of Nkx2-5 in the cardiac crescent
[18]. Gli2-/-Gli3+/- embryos have persistent truncus arter-
iosus (PTA) and a single outflow tract [19, 20]. SMO
agonist (SAG), which enhances HH signalling, increases
embryonic chick cardiac progenitor cell proliferation in
vivo and in vitro [21]. In zebrafish, treatment with SAG or
Shh enhances the number of cardiomyocytes in the devel-
oping cardiac chambers [22, 23], whereas treatment with
the HH signalling inhibitor, cyclopamine, reduces Nkx2-5
and Myhc expression as well as cardiomyocyte prolifera-
tion [22, 23]. Together these studies demonstrate that
functional HH signalling is important for regulating the
number of cardiac progenitor cells and heart development
in vivo.
D. melanogaster embryos lacking a single Mef2 gene do
not exhibit any muscle development [24]. In mammals,
there are four MEF2 members, MEF2A-D [25]. Expression
of a dominant-negative fusion protein of MEF2C with an
engrailed repression domain (EnR) under the regulation
of an Nkx2-5 enhancer (Nkx2-5-MEF2C/EnR), which
mediates the repression of all MEF2 target genes,
leads to severely disrupted cardiomyogenesis in mice
[26]. Mef2c-/- mice or mice with myocardium-specific
knockout of Mef2c, through either Myhc6-Cre or Mlc2v-
Cre, fail to undergo heart looping morphogenesis, as well
as correct development of the right ventricle and outflow
tract [8, 9]. Thus, MEF2 factors are important for early
heart development.
Differentiating mouse embryonic stem (mES) cells
share a similar hierarchical set of gene expression pat-
terns observed during cardiomyogenesis in vivo [27].
The mesoderm marker, Brachyury, and the precardiac
mesoderm marker, Mesp1, are expressed by days 3 and 4
of differentiation, respectively [27]; cardiac progenitor
genes Nkx2-5, Gata-4, Tbx5, and Mef2c are expressed
by day 6 [27–29]; and both alpha and beta isoforms of
MyHC proteins (MyHC6/α-MyHC and MyHC7/β-MyHC,
respectively) are expressed in mES cell-derived cardio-
myocytes [30]. Although mES cells serve as a useful in
vitro model system for studying molecular regulation of
cardiomyogenesis, the roles of HH signalling during mES
cardiomyogenesis have yet to be assessed.
The role of HH signalling and MEF2 factors during
cardiomyogenesis in vitro has been studied in P19 em-
bryonal carcinoma (EC) cells, a mES cell model system
[31–33]. P19 cells originate from a mouse teratoma, are
pluripotent, give rise to tissues in chimeric mice, and
can be induced to differentiate into cardiomyocytes
when treated with dimethylsulphoxide (DMSO) [34–36].
In P19 cells, overexpression of MEF2C, SHH, or GLI2 is
sufficient to induce and enhance cardiomyogenesis
through the upregulation of cardiac progenitor factors
like Nkx2-5 and Gata-4 [31, 33]. In agreement, P19 cells
treated with cyclopamine show delayed cardiomyogen-
esis [32], whereas expression of a dominant-negative
GLI/EnR or Nkx2-5-MEF2C/EnR results in reduced car-
diomyogenesis and Nkx2-5, Tbx5, Gata-4, and Myhc6
expression [33]. GLI2 and MEF2C can directly bind to
each other’s gene regulatory elements in P19 cells
undergoing cardiomyogenesis, form a protein complex,
and synergistically activate an Nkx2-5 promoter [33].
Therefore, HH signalling and MEF2C may regulate
cardiomyogenesis through a common pathway.
Chromatin remodelling factors modulate chromatin
density, which affects the ability of transcription factors
to regulate gene expression [37, 38]. The Brahma-
associated factors (BAF) belong to the switch/sucrose
non-fermentable (SWI/SNF) group of complexes and
mediate nucleosome shifting on chromatin in an ATP-
dependent manner [39]. When the ATPase BAF subunit,
Brahma-related gene 1 (BRG1/SMARCA4) is globally
knocked out, embryos do not survive past the peri-
implantation stage [40]. Embryos with a conditional
mutation of Brg1 in cardiac progenitor cells, using
Nkx2-5-Cre, have irregular ventricle morphology and
die by E10.5 [41]. Therefore, BRG1 is important during
heart development.
GLI3 and GLI1 proteins interact with BRG1 in the devel-
oping or postnatal brain, respectively [42]. Furthermore,
BRG1 is required for both HH target gene repression and
activation in mouse embryonic fibroblasts (MEFs), most
probably though an interaction with GLI3R and GLI1, re-
spectively [42], and is recruited to at least some HH target
genes in a HH signalling-dependent manner [42]. Although
GLI2 and BRG1 co-immunoprecipitate in MEFs, the im-
portance of this interaction has yet to be tested [42].
Given the role of HH signalling and BAF subunits dur-
ing cardiomyogenesis [18, 31–33, 41], the requirement
of BRG1 for HH target gene activation, and BRG1’s
ability to interact with GLI proteins [42], we hypothesized
that GLI2 and BRG1 may function together to regulate
cardiomyogenesis in vitro. Here we show that: 1) activa-
tion or suppression of HH signalling during mES cell car-
diomyogenesis regulates cardiac progenitor transcripts
Mef2c, Nkx2-5, and Tbx5; 2) GLI2 co-immunoprecipitates
with BRG1 in differentiating mES cells; and 3) BRG1
is recruited to the GLI2 target gene, Mef2c, in a HH
signalling-dependent manner in P19 cells undergoing
cardiomyogenesis.
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Methods
mES cell culture
D3 mES cells (ATCC, #CRL-1934) were cultured with
10 % fetal bovine serum (FBS, Wisent Inc.) and leukemia
inhibitory factor (LIF, Millipore). D3 cells were stably
transfected with the empty pcDNA3.1+ vector or the
pcDNA3.1+ vector expressing Flag-Gli2S662A, a full-
length complementary DNA of mouse Gli2 driven by
the CMV promoter, in frame with the Flag epitope and
containing the serine to alanine mutation at position 662
which prevents phosphorylation and proteasomal deg-
radation [43]. Stable clones were termed mES[Ctrl] and
mES[GLI2], respectively. Transfected colonies were se-
lected with 0.8 mg/ml Geneticin (GIBCO) and screened
for the highest FLAG-GLI2S662A transcription and pro-
tein expression levels by quantitative PCR (qPCR) and
western blot analysis, respectively (Additional file 1:
Figure S1 and data not shown). To induce differentiation,
mES cells were divided into 20 μl hanging drops at 800
cells/drop and allowed to form aggregates for two days
without LIF, as described in [44]. For immunoprecipitation
studies, mES cells were divided into 20 μl hanging drops
at 8000 cells/drop to allow for sufficient starting material.
The resulting embryoid bodies (EBs) were pooled and left
in suspension for three days. Then the EBs were trans-
ferred to tissue culture-treated (TC) plates (Corning) or
0.1 % gelatin-coated (Fisher Scientific) coverslips and cul-
tured until day 7, 10, or 15 for the analysis of cardiomyo-
genesis, neurogenesis, or skeletal myogenesis, respectively.
Medium was changed every two days. For HH inhibition,
KAAD-cyclopamine (Toronto Research Chemicals) or the
methanol vehicle, were added from day 3 to day 7 at a
final concentration of 3 μM where it was added every sec-
ond day with medium change. KAAD-cyclopamine- and
methanol-treated EBs were plated on 0.1 % gelatin-coated
coverslips and were cultured until day 7.
P19 EC cell culture
Parental P19 EC cells (ATCC, #CRL-1825) or P19 EC cells
transfected with either pcDNA3-GLI2 or an empty vector
control as described in [33, 45], termed P19[GLI2] and
P19[Ctrl], respectively, were cultured and differentiated as
per [46]. Briefly, the P19 EC cell differentiation was initi-
ated by plating 5x104 cells/ml with 1 % v/v DMSO (Sigma-
Aldrich) in non-adherent dishes. After 4 days in suspen-
sion, the newly aggregated EBs were transferred to TC
plates or 0.1 % gelatin-coated (Fisher Scientific) coverslips
without DMSO for an additional 2 days of the 6-day proto-
col. Throughout the differentiation process the EBs were
fed fresh medium with or without DMSO at least every
two days. To inhibit HH signalling in P19 EC cells, differ-
entiating P19 EC cultures were treated with 5 μM KAAD-
cyclopamine, as previously described [32], or with metha-
nol vehicle alone throughout the entire 6-day protocol.
Immunoprecipitation assays
To detect FLAG-GLI2S662A in the stable cell lines, total
protein extracts on days 2-5 of differentiation were
prepared by lysing cells in radioimmunoprecipitation
(RIPA) buffer [50 mM Tris pH7.5, 150 mM NaCL,
0.2 % NP-40, 2 mM EDTA, 1X PIC (Roche), 0.5 mM
PMSF (Sigma-Aldrich)]. The extracts were spun down
at 17,000 x g for 30 min and the lysates were collected.
300 μg of clarified total protein lysates was submitted
to immunoprecipitation with 20 μl of FLAG-beads
(FLAG-IP), as per Sigma-Aldrich’s protocol. Bound pro-
teins were eluted by boiling the beads in SDS-page sample
buffer for 10 min.
For mass-spectrometric analysis, FLAG-IP was per-
formed using 5 mg of nuclear protein extracts from day
3 differentiating mES[GLI2] and mES[Ctrl] cells as de-
scribed above except that the beads with bound proteins
were washed in wash buffer containing 300 mM NaCl.
For co-immunoprecipitation assay, 2 mg of total
protein lysate from day 3 differentiating mES[Ctrl]
and mES[Gli2] cell lines, prepared as described above,
was pre-cleared for 1 h using rec-Protein-G-Sepharose
beads (Invitrogen) and then were split equally and
subjected to immunoprecipitation with either mouse
IgG agarose beads as a negative control (Sigma-Aldrich)
or FLAG beads (Sigma-Aldrich). The immunoprecipita-
tion was performed as above except low salt wash buffer
was used (100 mM NaCl, 50 mM Tris pH7.5) and the
IP lasted for 2 h.
Immunoblot analysis
The resulting IP eluates and total protein (input) samples
were separated using a 4–12 % denaturing polyacrylamide
gel (NuPAGE, Invitrogen) with MOPS running buffer ac-
cording to the manufacturer’s protocol. The resolved pro-
teins were transferred to a polyvinylidene fluoride (PVDF)
membrane (Bio-Rad), blocked using non-fat dry milk
(Carnation) reconstituted with Tris-buffered saline and
Tween 20 (TBST), and incubated with GLI2- (kind gift
from C.C. Hui [47]), Brg1- (Millipore), FLAG- (Sigma-
Aldrich), or α-tubulin-specific (DM1A, Sigma-Aldrich)
antibodies. Membranes were stripped with re-blot plus
mild stripping buffer (Millipore) between each primary
antibody incubation. The signal was detected using
horseradish peroxidase (HRP)-conjugated secondary
anti-mouse (Cell Signalling) or anti-rabbit (Santa Cruz)
antibodies, followed by a chemiluminescence reaction
using Pierce ECL substrate (Fisher Scientific).
Densitometry was performed on the GLI2-specific
bands with the ImageJ program (National Institutes of
Health, USA) [48]. The densities of the GLI2 protein in
the FLAG-IP samples were normalized to the loading
control, α-tubulin, and were presented as a percentage
of the highest band density.
Fair et al. BMC Developmental Biology  (2016) 16:27 Page 3 of 19
Mass spectrometric analysis
Eluates from mES[Ctrl] and mES[Gli2] FLAG-IP, pre-
pared as described above, were resolved on a 4–12 % de-
naturing polyacrylamide gel (NuPAGE, Invitrogen) and
silver-stained. The staining identified a unique band pro-
file in the 170-250 kDa range of the mES[GLI2] sample
compared to the mES[Ctrl] sample (data not shown).
Resolved proteins from both cell lines, within the 170-
250 kDa range, were extracted from the gel using in-gel
digestion, according to [49]. The extracted samples were
submitted to liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) on a Thermo LTQ Orbitrap XL hy-
brid mass spectrometer with a nanospray ion source. The
MS/MS ion spectra were matched against the SwissProt
database (version 2013_05) using the MASCOT software
(Matrix Science, UK) with a peptide mass tolerance of
10 ppm and a fragment mass tolerance of 0.6 Da [50].
Quantitative PCR (qPCR) analysis
Total RNA from mES and P19 cells was isolated using
RNeasy Micro Kit (Qiagen) and E.Z.N.A. Total RNA Kit
(OMEGA Bio-tek) according to manufacturers’ instruc-
tions. cDNA was generated using at least 500 ng of total
RNA using the QuantiTect Reverse Transcription Kit as
per manufacturer’s protocol (Qiagen). A negative control
(no RT) was prepared alongside each experiment for every
cell line to control against genomic DNA contamination.
For each qPCR reaction, 1/40th of the resultant cDNA re-
action product, a final concentration of 200 nM transcript-
specific primers and either a GoTaq qPCR Master Mix kit
(Promega) or a KAPA SYBR® FAST qPCR kit (KAPA Bio-
systems) were used to detect transcripts of interest in a
given sample with an Eppendorf realplex2 Mastercycler.
The primer sequences are listed in Table 1. Threshold
amplification cycles (Ct) values were determined for
each sample, and normalized to the β-actin control using
the 2-ΔΔCt method [51]. The relative fold changes were
presented as a percentage of the highest transcriptional
expression for each respective gene (percent maximum),
as described in [33, 52, 53]. All error bars represent ±
standard error of the mean (SEM) from three or more in-
dependent biological replicates. All statistical analyses
were done using Student’s T-tests.
Immunofluorescence
Day 7 differentiated mES cells were fixed in −20 °C MeOH
(Fisher), incubated 1:1 with monoclonal MF20 antibody
supernatant [54] in phosphate buffered saline (PBS) and
Cy3-conjugated goat anti-mouse IgG (Jackson Immuno
Research) 1:100 in PBS to detect pan-MyHC expression.
Coverslips were mounted in 50 parts PBS, 50 parts
glycerol (Fisher), and 1 part Hoechst 33258 dye for stain-
ing nuclei. Indirect immunofluorescence of MyHC was
visualized using a Leica DMI6000B inverted fluorescent
microscope (Leica Microsystems GmbH) and captured
with a Hamamatsu Orca AG camera (Hamamatsu Photon-
ics). Pictures were processed with the Volocity 4.3.2 soft-
ware (Perkin Elmer). Cells were counted based on the
number of nuclei and identified as MyHC+ve or MyHC-ve
using the Volocity imaging program with automated cell-
identification parameters as described in ref. [44]. To meas-
ure the intensity of MHC signal, the outline of at least 10
MyHC+ve individual cells in 10 random fields of view per
each cell line and experiment was drawn using the software
ImageJ. The intensity of the MHC staining in each outlined
cell was measured, together with several background
measurements. The corrected intensity values = integrated
density - (cell area x mean intensity reading for the back-
ground) was calculated as in McCloy et al [55]. To assess
proliferation, day 7 cells were treated with 10 μM EdU for
1 h prior to fixing with 3.7 % formaldehyde and then con-
tinuing with the EdU staining protocol (Invitrogen).
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed as previously described [56]
using 25 μg of chromatin from day 4 differentiating
P19[GLI2] or P19[Ctrl] cells and 2 μl of anti-SNF2β/
BRG1 (07-478, Millipore) antibodies or Normal Rabbit
Serum (NS01L, Calbiochem). Briefly, EBs from 10 plates
(150 mm) were fixed with 1 % formaldehyde (Fisher Sci-
entific) for 60 min before isolating and shearing chroma-
tin as per [56]. The chromatin-antibody complexes were
captured with BSA-blocked rec-Protein G-Sepharose 4B
Conjugated beads (Invitrogen). Eluted complexes were
treated with RNase A (Sigma-Aldrich) and Proteinase K
(Roche), to remove contaminating RNA and proteins,
Table 1 Sequences of primers used for real time qPCR analyses
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respectively. The DNA was purified using a QIAquick
PCR Purification Kit (Qiagen). To detect eluted DNA
fragments, qPCR analyses were performed using 1/40th of
each eluted sample, per reaction, with sequence-specific
primers listed in Table 2, as mentioned above. For every
qPCR reaction, a standard curve was generated to analyze
the enrichment of BRG1- or IgG-associated genomic
elements from the input sample.
Chromatin from KAAD-cyclopamine- or MeOH-treated
P19 EC cells was prepared as above with the following
adapted fixing and sonication conditions. Cells from 4
plates of day 4 P19 EC EBs - treated with KAAD-
cyclopamine or MeOH - were fixed with 1.5 mM Ethylene
glycol bis[succinimidylsuccinate] (EGS) (Thermo Scientific)
for 30 min alone, then with 1 % formaldehyde (Sigma-
Aldrich) for an additional 30 min. Chromatin was soni-
cated in 1 mL, 12x12 AFA tubes (Covaris) for 30 min with
an S220 Focused-ultrasonicator (Covaris) as per manufac-
turer’s recommended operating conditions for a target
200-700 bp fragment range. The IP of these samples
was done using 20 μg of chromatin. The qPCR analyses
were performed, as above, but with 1/50th of each
eluted sample, per reaction.
Bioinformatics analysis
BRG1 genome-wide ChIP-sequencing peaks described in
undifferentiated mES cells [57] were screened for overlap-
ping conserved GLI consensus binding motifs, which were
identified with the Multiple Sequence Local Alignment
and Visualization tool (Mulan) as described in [58]. The
nearest genes within 50 kb of these overlapping sites in the
mouse genome (mm9 genome assembly) were categorized
by gene ontology (GO) biological process analysis using
the Genomic Regions Enrichment of Annotations Tool
(GREAT) bioinformatics system as described in [59]. The
entire set of BRG1 target genes in mES cells [57] was used
as background for assessing the enrichment of these identi-
fied genes.
Results
Overexpression of FLAG-GLI2S662A results in increased
levels of GLI2 protein during mES cell differentiation
Since GLI2 protein is prone to degradation when phos-
phorylated [60], we chose to stably transfect mES cells
with a Flag-Gli2S662A, a vector used to express a stabi-
lized version of GLI2 [43]. qPCR showed that over the
course of differentiation, transgene expression declines
in all four clones analyzed (Additional file 1: Figure S1),
possibly reflecting post-transcriptional down-regulation of
the Gli2 mRNA or transcript. We note that the Gli2S662A
mRNA that we expressed contains the entire 3’ untrans-
lated region of the gene and as such could be subjected
to microRNA-mediated downregulation [61, 62]. A similar
downregulation was observed when we expressed a
different transcription factor in pluripotent cells [63].
Importantly, the expression of Gli2S662A mRNA persisted
in all clones, albeit at lower levels throughout differenti-
ation (Additional file 1: Figure S1). For subsequent ex-
periments, we selected clone #3, with the highest and
most stable levels of Gli2 mRNA during differentiation
(Additional file 1: Figure S1). From here on, this clone is
referred to as the mES[GLI2] cell line, while control mES
cells transfected with only a Flag peptide tag-containing
vector (clone Flag#1) are referred to as the mES[Ctrl]
cell line.
mES[GLI2] and mES[Ctrl] cell lysates were then tested
for the presence of exogenous FLAG-GLI2S662A protein by
immunoprecipitation with anti-FLAG beads (FLAG-IP)
and sequential western blot analysis with GLI2 antibodies
(Fig. 1a, first row of blots). We observed a significant en-
richment of total GLI2 protein levels in mES[GLI2] cells
when compared to mES[Ctrl] on days 2-5 of differentiation
Table 2 Sequences of primers used for ChIP-qPCR analyses
Target Location (mm10) Forward primer Reverse primer
β-actin Chr 5:142,906,954 - 142,907,148 GATGCTGACCCTCATCCACT ATGAAGAGTTTTGGCGATGG
Gene Desert Chr 15: 70,644,478 - 70,644,564 TCCTCCCCATCTGTGTCATC GGATCCATCACCATCAATAACC
Mef2c site A Chr 13: 83,417,148 - 83,417,378 TGAAAAAGGAAATATCCCACTTAGA TTGCATGGGTTCACACCTAA
Mef2c site B Chr 13: 83,450,400 - 83,450,695 AGTTGCCTGAGCCTGTTTTC TTTTTCGGCAATGATTTTCC
Mef2c site C Chr 13: 83,517,957 - 83,518,157 CTTTCGGCTGGAGAGTCTTG TCTCCAGTTCCTGGGAAGAA
Mef2c site D Chr 13: 83,524,812 - 83,524,937 ACACACGCACACTTCGTCTC GACCCACACAGAACCTTCAAA
Mef2c site E Chr 13: 83,595,419 - 83,595,594 TTCCCATTTGGACCATTACC ACCCACGCACTGAGACTTTC
Mef2c site F Chr 13: 83,633,148 - 83,633,305 AACCCCAATCTTCTGCCACT AAGCTTTCGCTAGACGTGGA
Mef2c site G Chr 13: 83,660,831 - 83,661,075 GAGCCCCCTCTCTAATGTCC TGTGGGCAAGTGTCTTTCTG
Mef2c site H Chr 13: 83,664,180 - 83,664,382 AAGTGACATTTGGGGGTCCT CGACCGACCTGCTTTACTTG
Mef2c site I Chr 13: 83,739,543 - 83,739,715 CCTAATTATTTCAGTTTGGGATGC CCTCCCCTCTTGTCAAAGTGT
Chr Chromosome
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(Fig. 1a, second row of blots, upper band). We found ~8-
fold and ~13-fold enrichment of total GLI2 protein level in
mES[GLI2] cells when compared to mES[Ctrl] on days 2
and 3 of differentiation, respectively (Fig. 1a, second row of
blots), and over-expression persisted on days 4 and 5, when
no GLI2 protein was detectable in the mES[Ctrl] cell
line at this exposure level. Overall, these results show
that the GLI2 protein was overexpressed in mES[GLI2]
cells during early stages of mES cell differentiation
compared to the control.
Comparable results were also observed at the tran-
scriptional level. Flag-Gli2S662A transcripts were only
expressed in the mES[GLI2] cells and were at the high-
est level in the undifferentiated (day 0) mES[GLI2] cells
(Fig. 1b, panel Flag-Gli2S662A), and this was mirrored by
total Gli2 transcript levels (Fig. 1b and Additional file 1:
Figure S1). Such a trend has been noted in other pub-
lished work on differentiating mES cells [33]. Thus, the
stability of the exogenous GLI2S662A protein, which re-
mains higher during the differentiation of mES[GLI2]
cells compared to controls, is a key element in our
model system.
Overexpression of GLI2 results in enhanced cardiac
progenitor gene expression
To assess the efficacy of the GLI2 overexpression, we
monitored the expression of the GLI2 target gene, Ptch1
[64]. Overexpression of GLI2 resulted in a significant
Fig. 1 Overexpression of GLI2 protein in mES[GLI2] cultures is maintained during differentiation. a Total protein extracts from corresponding
differentiating cells were analyzed using immunoblot with GLI2 antibodies, with or without prior FLAG-IP. α-tubulin was used as a loading control.
Relative band densities are listed below blots. The size of the upper band in the total protein blots ~180 kDa, is consistent with other studies
[33, 67] and equivalent to the single GLI2 band that was pulled down by FLAG-IP. ( ) The non-specific binding seen below the GLI2 band is
typical of this antibody [33, 47, 67]. b Transcription levels of the indicated genes in differentiating mES[Ctrl] (white bars) and mES[Gli2] (grey bars)
cells were quantified using qPCR. Expression levels were normalized to β-actin, calibrated to day 0 mES[Ctrl] culture expression levels, and presented as
a percentage of the highest expression level recorded, per gene. Error bars represent +/- SEM. The number of biological replicates analyzed
(n) is indicated beside each graph. (†) n = 4 for total Gli2 days 0 and 4. One-tailed Student’s T-tests were used for statistical analyses. Grey lines
represent paired T-tests; black lines represent unpaired T-tests; ( ) p < 0.05
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2.9 ± 0.7-fold increase of Ptch1 transcripts in undifferenti-
ated mES[GLI2] cells and a significant 1.4 ± 0.2-fold in-
crease in day 2 differentiating mES[GLI2] cells compared
to control cells (Fig. 2, panel Ptch1). Therefore, the over-
expression of GLI2 in mES cells increased GLI2 target
gene expression.
During differentiation, both the mES[Ctrl] and
mES[GLI2] cell lines showed a similar transition through
the mesoderm stage of differentiation, as no significant
difference was detected for the levels of Brachyury tran-
scripts by day 4 between these two cell lines (Fig. 2, panel
Brachyury). Mesp1 levels were significantly upregulated in
the mES[GLI2] cultures as compared to control cultures
on day 4 of differentiation, however, its level of expression
was minor as compared to day 6 values and was not
significantly higher than day 0 basal levels (Fig. 2, panel
Mesp1). On day 6, no significant difference between
mES[Ctrl] and mES[GLI2] cell lines was detected for
the Mesp1 expression. Based on this analysis, the meso-
derm and precardiac mesoderm stages of cardiomyo-
genesis during mES cell differentiation did not appear
to be significantly regulated by GLI2 overexpression.
These results are supported by previous reports, which
showed that modulation of HH signalling in mouse P19
EC cells did not significantly regulate mesoderm induc-
tion [31–33].
The cardiac progenitor transcripts Nkx2-5, Mef2c, and
Tbx5 were significantly upregulated in the mES[GLI2]
cultures on day 6 of differentiation as compared to
mES[Ctrl] cells (Fig. 2; panels Nkx2-5, Mef2c, and Tbx5).
Interestingly, overexpression of GLI2 had no effect on
day 6 Gata-4 transcript levels (Fig. 2, panel Gata-4).
Fig. 2 Overexpression of GLI2 in mES cells enhances transcript expression of a GLI2 target and of cardiac progenitor-enriched genes.
qPCR analysis of mRNA expression of indicated genes known to be active in HH-responsive cells, mesoderm/precardiac mesoderm cells,
and cardiac progenitor cells, in mES[Ctrl] (white bars) and mES[Gli2] (grey bars) cultures on the days noted in the figure. Expression levels
were normalized to β-actin, calibrated to day 0 mES[Ctrl] culture expression levels, and presented as a percentage of the highest expression level
recorded, per gene. Error bars represent +/- SEM. The number of biological replicates analyzed (n) is indicated on each graph. One-tailed Student’s
T-tests were used for statistical analyses. Grey lines represent paired T-tests; black lines represent unpaired T-tests; ( ) p< 0.05
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Therefore, overexpression of GLI2 during mES cell dif-
ferentiation resulted in enhanced transcription levels of
select cardiac progenitor genes. Our data supports and
extends previous publications, where overexpression of
GLI2 was shown to induce and enhance cardiac progeni-
tor gene expression in P19 EC cells [31, 33].
We tested whether cells of the skeletal muscle and
neuronal lineages were affected, since GLI2 and HH
have been shown to regulate these processes [14, 65, 66].
However, we did not detect any significant increase in the
mRNA levels of Pax3 (Additional file 2: Figures S2A), a
gene involved in skeletal myogenesis and downstream of
GLI2 [45, 53, 67, 68], or in MyHC-positive skeletal myo-
cytes (data not shown as none of the cultures contained
any skeletal myocytes after 10 days of differentiation). A
significant increase in Ascl1, a gene involved in neural
progenitor differentiation that is downstream of GLI2 and
HH signalling [67, 69–71], was detected (Additional file 2:
Figure S2B). However, none of the cultures contained
NF68-positive neurons, even after 10 days of differenti-
ation (negative data not shown).
Overexpression of GLI2 does not result in an increased
number of cardiomyocytes
To determine if the enhancement of select cardiac pro-
genitor transcripts led to an overall enhancement of cardi-
omyocytes in mES[GLI2] cultures, we counted MyHC+ve
cells in day 7 mES[Ctrl] and mES[GLI2] cultures (Fig. 3a).
On average, 8.3 ± 2.6 % and 12.4 ± 5.9 % of the total cells
counted were MyHC+ve in the mES[Ctrl] and mES[GLI2]
cultures, respectively (Fig. 3b). Similar percentages have
been shown before by analysis of MyHC, MLC2v and
tropomyosin in day 7 or 8 differentiating mES cells,
differentiated using the hanging drop method [44, 72].
Although there was a trend towards an increase in cardio-
myocytes in the mES[GLI2] cultures compared to the
control, the variability between the samples across three
biological replicates (Fig. 3b) and another four additional
replicates (data not shown) resulted in no significant
difference in the percentage of MyHC+ve cells on day 7.
Although overexpression of GLI2 during mES cell
differentiation also did not significantly affect the level of
Myh6 or Myh7 transcripts on day 7 (Fig. 3c), we observed
Fig. 3 Overexpression of GLI2 does not significantly upregulate the number of MyHC+ve cells. a MyHC+ve cells (red) were visualized and (b) counted in
corresponding day 7 differentiating cells by indirect immunofluorescence. Hoechst (blue) was used to visualize nuclei. Representative images of the
cardiomyocyte-enriched areas on the periphery of an EB are shown. Scale bar represents 100 μm. At least 2500 nuclei were counted across 20 random
fields of view, per biological replicate; n = 3. c Myhc6/7 expression levels on the days indicated in mES[Ctrl] (white bars) and mES[Gli2] (grey bars)
cells were normalized to β-actin, calibrated to day 0 mES[Ctrl] culture expression levels, and presented as a percentage of the highest expression level
recorded, per gene. Error bars represent +/- SEM; n = 3. One-tailed Student’s T-tests were used for statistical analyses. Grey lines represent
paired T-tests; black lines represent unpaired T-tests; ( ) p < 0.05. d MyHC+ve cells from (a) were analyzed for MyHC signal intensity using the ImageJ
program. At least 100 cells were analyzed across 10 random fields of view per biological replicate; n = 2
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a notable increase in MyHC signal intensity in cardiac
myocytes in mES[GLI2] cultures (Fig. 3d). This sug-
gests that although the number of cardiomyocytes
formed is unchanged, the presence of exogenous GLI2
is associated with a trend towards higher MyHC pro-
tein expression.
To test if overexpression of GLI2 had any effect on cell
proliferation or apoptosis, we first analyzed EdU-positive
cells. When cultures were analyzed for the presence of
EdU-positive cells on day 7, there was no difference be-
tween mES[Ctrl] and mES[Gli2] cell lines (Additional file 3:
Figure S3A). Of note, we also did not observe any differ-
ences in RNA yields between mES[Ctrl] and mES[Gli2]
cultures throughout the 7-day differentiation protocol
(Additional file 3: Figure S3B). This supports that overex-
pression of GLI2 did not have any overt effects on cell
proliferation. Lastly, we analyzed cells with fragmented
nuclei as a classical hallmark of apoptosis. Notably, there
was no difference in the proportion of apoptotic cells
in mES[Gli2] cultures when compared to mES[Ctrl]
(Additional file 3: Figure S3C). Thus, overexpression
of GLI2 did not have any effect on cell proliferation
or survival in differentiating mES cells.
Antagonizing the HH pathway leads to lower cardiac
progenitor gene expression
A previous report demonstrated active HH signalling
during mES differentiation [33]. Our results showing in-
duced levels of Ptch1 expression, a readout of active HH
signalling, during mES(Ctrl) differentiation (Fig. 2, panel
Ptch1), are in line with this observation. Thus, following
the results from gain-of-function experiments, we pro-
ceeded to investigate the involvement of GLI2 through
loss-of-function experiments. For this, we utilized a syn-
thetic derivative of cyclopamine, KAAD-cyclopamine,
which is approximately 10-20 times more potent than
cyclopamine without being more toxic [73] and has pre-
viously been shown to successfully inhibit HH signalling
in a variety of cells, such as P19 EC cells, C3H10T1/
2 fibroblasts, and adult skeletal muscle satellite cells
[32, 53]. HH inhibition was monitored by the downregu-
lation of Ptch1 mRNA, a marker of active HH signalling
[74]. KAAD-cyclopamine treatment resulted in a 69 ± 6 %
decrease in Ptch1 expression on day 7 of mES cell differ-
entiation, as compared to vehicle-treated cells (Fig. 4a).
HH inhibition also resulted in comparable decreases in
expression of Nkx2-5, Gata-4, Tbx5 and Mef2c (Fig. 4a).
We also noted a significant, albeit more modest, decrease
in Myh7 expression (Fig. 4a). By immunofluorescence,
we noted a slight, not statistically significant decrease
in the number of myosin heavy chain-positive cells
(Fig. 4b and c). To rule out that the observed effect on
MyHC cardiac myocytes was not due to aberrant cell pro-
liferation or apoptosis, we first tested the RNA yields from
identical plates of vehicle and cyclopamine treated cul-
tures. Throughout 7-day differentiation protocol, there
was no difference in the amount of RNA harvested
from vehicle-control and cyclopamine treated cultures
(Additional file 3: Figure S3D), suggesting that there was no
overt effect on cell proliferation in the presence of cyclopa-
mine. To test for aberrant apoptosis, cells with fragmented
nuclei were analyzed (Additional file 3: Figure S3E). These
controls rule out the possibility that cell density or survival
differences elicited by cyclopamine treatment would have
caused the phenotype we observed. Together, our results
on HH activation (GLI2 overexpression, Fig. 2) and inhib-
ition (KAAD-cyclopamine treatment, Fig. 4) support the
notion that HH signaling is important for cardiac progeni-
tor gene expression, similarly to previous reports in P19
cells [31, 32].
GLI2 interacts with BRG1 during mES cell differentiation
We further sought to elucidate the molecular mecha-
nisms behind the enhanced Mef2c, Nkx2-5, and Tbx5
transcription levels on day 6 of mES cell differentiation
by GLI2 overexpression. To identify potential GLI2-
interacting proteins, we performed a mass spectrometric
and western blot analysis of the FLAG-IP on mES[GLI2]
and mES[Ctrl] cell nuclear extracts from day 3 differen-
tiating cells. BRG1, an active member of the BAF
chromatin-remodelling complex was identified and had
a higher Mascot score in the mES[GLI2] sample than
the mES[Ctrl] sample, in the mass spectrometry assay
(data not shown). A sequential western blot assay with
anti-GLI2 antibodies confirmed immunoprecipitation of
GLI2 protein in mES[GLI2], but not in mES[Ctrl] cells
(Fig. 5a). When the same blot was re-probed with anti-
BRG1 antibodies, co-immunoprecipitation of BRG1 with
FLAG-GLI2S662A was observed (Fig. 5a). The co-IP BRG1
signal in the mES[GLI2] cells was not merely due to mod-
ulated levels of Brg1 expression, as both mES[Ctrl] and
mES[GLI2] samples showed no significant difference in
Brg1 mRNA transcript levels during the first four days of
differentiation (Additional file 3: Figure S3A). Our results
showing co-precipitation of BRG1 with GLI2 are similar
to those reported by others using NIH 3 T3 cells, where
BRG1 was found to interact with HA-tagged GLI proteins,
including GLI2 [42].
The observed co-immunoprecipitation of GLI2 and
BRG1 during mES cell differentiation led to our hypoth-
esis that GLI2 could recruit BRG1 to regulatory regions
of GLI2 target genes to modulate their expression.
Given the results and the known roles of BRG1 and
GLI2 in heart development [19, 20, 41], we were inter-
ested in knowing if GLI2 and BRG1 could co-regulate
key cardiac progenitor genes implicated in cardiomyo-
genesis. Mef2c, which is important for proper mamma-
lian heart development [8, 75], was enhanced in day 6
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differentiating mES[GLI2] cells compared to mES[Ctrl]
cells (Fig. 2) and was recently identified as a direct
target of GLI2 during P19 EC cell cardiomyogenesis
[33]. Thus, we set out to determine if BRG1 associates
with GLI2-bound Mef2c regulatory elements in a HH-
dependent manner. Since mES cells spontaneously dif-
ferentiate into lineages of all three germ layers [76] and
BRG1 is expressed in many mammalian cells and tis-
sues [39], it is difficult to answer this question in the
context of endogenous mES cell cardiomyogenesis. In
contrast, P19 EC cells predominantly differentiate into
cardiomyocytes by day 6 of differentiation, along with
skeletal myogenic progenitors and fibroblast-like cells
when treated with DMSO [35, 77, 78]. Moreover, P19
EC differentiation is very similar to mES myogenic dif-
ferentiation [33, 44, 79, 80]. For these reasons, we used
P19 cells to determine the role of BRG1-GLI2 protein
complex during myogenic differentiation.
Fig. 4 HH signalling blockade prevents the induction of GLI2 target and of cardiac progenitor-enriched genes. a qPCR analysis of mRNA expression of
Ptch1 and indicated cardiac progenitor-enriched genes in day 0 mES cells (white bars) or in cultures kept in differentiation condition for 7 days, in the
presence of KAAD-cyclopamine (black bars) or vehicle (methanol, grey bars). Error bars represent +/- SEM; n = 3 ( ) p < 0.05 by one-tailed paired T-test.
b Immunofluorescence detection of myosin heavy chain (red channel) in similar day 7 cultures treated with vehicle or KAAD-cyclopamine. DNA was
counterstained with Hoechst (blue channel). c MyHC+ve cells from (b) were counted. Error bars represent +/- SEM; n = 3 biological replicates
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Fig. 5 (See legend on next page.)
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BRG1 associates with Mef2c regulatory elements in HH
signalling dependent manner
In line with what has been shown previously [81], we
determined that Brg1 is expressed throughout the differ-
entiation of mES and P19 cells, and that GLI2 over-
expression does not drastically affect its expression in
either (Additional file 4: Figure S4). Our lab has previ-
ously shown that GLI2 associates with eight of the nine
conserved GLI consensus binding motifs found in the
Mef2c gene on day 4 of P19[GLI2] cell differentiation
(Mef2c sites B-I) (Fig. 5b and Table 3) [33]. Given that
BRG1 immunoprecipitates with GLI2, we performed an
anti-BRG1 ChIP on chromatin from day 4 differentiating
P19[Ctrl] and P19[GLI2] cells, to determine if BRG1 as-
sociates with GLI2-specific Mef2c genomic elements
during differentiation, and also if GLI2 overexpression
can modulate this potential association. Notably,
P19[GLI2] cells exhibited enhanced cardiomyogenesis
as measured by an increased percentage of cardiomyo-
cytes and higher expression levels of cardiac progenitor
genes on day 6 of differentiation, in agreement with previ-
ous reports (references [31, 33] and data not shown).
(See figure on previous page.)
Fig. 5 Overexpression of GLI2 recruits BRG1 to a GLI2-specific Mef2c gene element. a Anti-Flag immunoprecipitation in nuclear extracts from day
3 mES[GLI2] or mES[Ctrl] cells. Immunoprecipitated proteins were probed by western blot using anti-BRG1 or anti-GLI2 antibodies. b A schematic
representation of the Mef2c gene and its major sites of interest. The scale bar represents coordinates of the Mef2c gene in the mouse genome
(mm10 genome assembly). This schematic was constructed using the UCSC Genome Browser (http://genome.ucsc.edu), TRANSFAC, and data from
previous publications [33, 82–84, 94, 96–101]. GLI-specific Mef2c sites A-I are marked with beige circles. GLI2 has been shown to bind only sites
B-I (circles outlined in grey). Other associating proteins, including BRG1 and MyoD, are depicted with coloured circles as outlined in the legend.
A detailed description of the associating protein sites can be found in Table 3. Chr: Chromosome. SHF I: ISL-1-dependent SHF enhancer. SHF II:
NKX2-5/FOXH1-dependent SHF enhancer. c Anti-BRG1 ChIP was performed on day 4 differentiating P19[GLI2] and P19[Ctrl] cultures with sequential
qPCR analyses of GLI-specific Mef2c sites A-I, depicted in (B). One-tailed Student’s T-tests were used for the ChIP statistical analyses; n = 3. All error bars
represent +/- SEM. All grey lines represent paired T-tests; all black lines represent unpaired T-tests; ( ) p < 0.05. d Gli1 and Brg1 mRNA expression levels
were assessed by qPCR in differentiating P19 EC cultures, treated with MeOH vehicle or KAAD-cyclopamine. These levels were normalized to β-actin
and presented as a fold-change over MeOH-treated culture expression levels from the same day. e The effect of KAAD-cyclopamine (black bars) or
vehicle (grey bars) treatment on the expression level of Gli1 and indicated cardiomyogenesis-specific genes was assessed using qPCR analysis.
Expression levels were normalized to β-actin, calibrated to day 0 untreated culture expression levels, and presented as a percentage of the
highest expression level recorded, per gene. f Anti-BRG1 ChIP was performed on day 4 differentiating P19 EC cultures that were treated with
either MeOH vehicle (grey bars) or KAAD-cyclopamine (black bars). Each ChIP was followed by qPCR analyses on a gene desert region (negative
control), β-actin (positive control), and Mef2C site C from panel b. All error bars represent +/- SEM; n = 3. Two-tailed Student’s T-tests were used for
statistical analyses. All grey lines represent paired T-tests; all black lines represent unpaired T-tests; ( ) p < 0.05
Table 3 A selection of proteins that associate with the Mef2c gene
Protein Mef2c domain Target Sequencea Location (mm10: Chr 13) Source of Protein Referencesb
BRG1 - - 83.504,012 - 83,504,138 Mouse [84]
MEF2C MADS-box acctttacagCTAAATTTACtccagagtg 83,504,087 - 83,504,115 Mouse [94]
MyoD E-box gagtgacatgaaCAGGTGcaccctggcct 83,504,111 - 83,504,139 Mouse [94]
E12 E-box gagtgacatgaaCAGGTGcaccctggcct 83,504,111 - 83,504,139 Mouse [94]
GATA-4 GATA-d taagagttcTTATCAgtgtc 83,523,287 - 83,523,306 Rat [82]
GATA-p gtcacccgctatCTATCGgtcagg 83,523,351 - 83,523,374
ISL-1 ISL-d gtcaggggagcCTAATGcatttgggaa 83,523,369 - 83,523,395 Hamster [82]
ISL-p ggtttacttgCTAATGacctggataa 83,523,405 - 83,523,430
SOX10 SOX gaatgcactgacTACAAAGtgcatcctgaag 83,565,883 - 83,565,913 Mouse [96]
Binding ggccatttagctCACAATGaaggtctgtgtt 83,565,913 - 83,565,943
Site aaatagctctatAACAAAGtaactacagagt 83,565,947 - 83,565,977
ETS1 ETS-A agttactcTCTTCCTGttatgaca 83,582,754 - 83,582,777 Mammalian [97, 98]
ETV2 ETS-A agttactcTCTTCCTGttatgaca 83,582,754 - 83,582,777 Mammalian [97]
FOXC1 FOX-NC ggaagttactctcttccTGTTATGacaggaaagcgtagaca 83,582,752 - 83,582,791 Mouse [97]
FOXC2 FOX-NC ggaagttactctcttccTGTTATGacaggaaagcgtagaca 83,582,752 - 83,582,791 Mouse [97]
FOXO1 FOX-NC ggaagttactctcttccTGTTATGacaggaaagcgtagaca 83,582,752 - 83,582,791 Mouse [97]
Chr Chromosome
aUppercase nucleotides in the target sequence represent nonconsensus binding domains
bAll binding site information for proteins, except BRG1 and SOX10, were compiled with information gathered through TRANSFAC
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Results from the anti-BRG1 ChIP showed an associ-
ation of BRG1 with Mef2c sites C, D, and G-I in the
P19[Ctrl] cells as compared to ChIP with a non-specific
rabbit serum control (Fig. 5c). Notably, although there
was a similar trend in the P19[GLI2] cells, we did not
observe statistical significance for BRG1 association on
sites D and G-I when compared to non-specific rabbit
serum (Fig. 5c). Mef2c site A, which lacked GLI2 associ-
ation under the same experimental conditions in a pre-
vious study [33], showed no significant association with
BRG1 in either cell line (Fig. 5c). However, the associ-
ation of BRG1 with the Mef2c site C was significantly
(p < 0.05) higher in P19[GLI2] cells as compared to
P19[Ctrl] cells (Fig. 5c). This effect was not due to al-
tered BRG1 expression in P19[GLI2] cells as there was
no significant change in Brg1 expression in P19[GLI2]
cells, as compared to P19[Ctrl] cells, on day 4 of dif-
ferentiation, when the ChIP assay was performed
(Additional file 4: Figure S4B).
Mef2c site C is of significant interest as it is located
proximally to the ISL-1-dependent SHF enhancer region
[82] (Fig. 5b, SHF1), it is upstream of the start site of a
transcript expressed in the developing heart [83], and it is
also the closest GLI2-binding site to a region previously
shown to associate with BRG1 [33, 84] (Fig. 5b, light blue
circle). Thus, as overexpression of GLI2 resulted in in-
creased association of BRG1 with Mef2c site C, we chose
this site to further investigate the dependence of BRG1 as-
sociation on endogenous HH signalling during P19 EC
cell cardiomyogenesis. KAAD-cyclopamine treatment of
P19 EC cells resulted in a 71.7 ± 17.0 % and 60.5 ± 25.0 %
decrease in Gli1 expression on days 4 and 6 of P19 EC
cell differentiation, respectively, without significantly
affecting the day 4 or 6 Brg1 transcript levels, compared
to treatment with a vehicle control (Fig. 5d). Similar
cyclopamine-mediated reductions of Gli1 expression
have been seen before in P19, P19CL6, and mES cells
[32, 85, 86]. By day 6, differentiating P19 EC cells
treated with KAAD-cyclopamine expressed significantly
lower Mef2c (45.9 ± 16.7 %), Gata-4 (74.8 ± 12.2 %), and
Tbx5 (65.4 ± 5.9 %) transcript levels, compared to dif-
ferentiating cells treated with the vehicle control
(Fig. 5e; panels Mef2c, Gata-4, and Tbx5). These lower
levels of cardiac progenitor-enriched transcripts were
expected as cyclopamine-treated P19 EC cells have re-
pressed Gata-4 expression [32] and cyclopamine-treated
P19CL6 EC cells show lower levels of Gata-4 and Nkx2-5
transcripts [85] and we showed that a similar treatment
in mES cells has a comparable effect (Fig. 4). Neither
the level of contractile protein transcripts in the day 6
differentiated cells (Fig. 5e, panels Myhc6 and Myhc7)
nor the number of MyHC+ve cardiomyocytes (data not
shown) significantly differed between KAAD-cyclopamine
and vehicle-treated P19 EC cells. This is supported by
previous reports, where differentiating P19 EC cells
treated with cyclopamine did not show any difference in
the number of MyHC+ve cardiomyocytes [32]. Thus, in-
hibition of HH signalling downregulated, but did not abol-
ish, normal expression of cardiac progenitor specific
transcripts and, overall, did not repress the formation of
cardiomyocytes, in agreement with [32].
To test if inhibition of HH signalling attenuated the
ability of BRG1 to associate with Mef2c site C, we per-
formed an anti-BRG1 ChIP in day 4 differentiating P19
EC cells treated with vehicle or KAAD-cyclopamine
(Fig. 5f ). The association of BRG1 with Mef2c site C in
P19 EC cells was significantly reduced upon HH inhib-
ition (Fig. 5f ). Importantly, KAAD-cyclopamine treat-
ment had no significant effect on BRG1’s association
with β-actin a known target of BRG1 in mES cells [57].
A gene desert locus was used as a negative control and
showed no significant association with BRG1. Therefore,
HH signalling is required, at least to some extent, for
the efficient association of BRG1 to the GLI2-specific
Mef2c gene element C.
Discussion
In this study we have shown that 1) GLI2 enhances the
expression of cardiac progenitor-enriched genes while
blocking HH signalling through cyclopamine decreases
the expression of cardiac progenitor-enriched genes; 2)
GLI2 immunoprecipitates with BRG1 during mES cell
cardiomyogenesis; and 3) BRG1 is recruited to a GLI2-
specific Mef2c gene element in a HH-dependent manner.
Thus, we propose a model, where HH/GLI2 regulates
the expression of Mef2c via the recruitment of BRG1
to the Mef2c gene element upstream of the SHF ele-
ments to ultimately regulate cardiomyogenesis in stem
cells (Fig. 6).
HH signalling is important for cardiac progenitor gene
expression during mES cell differentiation
Using a stabilized GLI2 mutant, we have shown that
GLI2 enhances early expression of cardiac progenitor
transcripts such as Mef2c, Nkx2-5, and Tbx5 during
mES cell cardiomyogenesis (Fig. 2). In agreement, when
HH signalling in mES cells is blocked with cyclopamine,
this leads to a great reduction in the expression of these
genes (Fig. 4). This supports and expands previous re-
ports in P19 EC cells [32, 33].
The effect of cardiac progenitor gene upregulation by
exogenous Gli2 is probably not due to an increase in
mesodermal transcript expression as GLI2 overexpres-
sion does not have any significant effect on the levels of
Brachyury or Mesp1 on days 4 and 6, respectively (Fig. 2).
Notably, the small upregulation of Mesp1 transcript
levels on day 4 in mES[GLI2] cells is minor in comparison
with day 6 values. This is in agreement with previous
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studies, which demonstrate that there is no significant
HH-dependent effect on mesoderm transcripts in P19
EC cells [31–33].
The enhanced expression of Nkx2-5 in mES[GLI2]
cells correlates with the HH-mediated expression of
Nkx2-5 in vivo [4, 18] and in P19 EC cells [31–33]. The
upregulation of Tbx5 transcript levels in differentiating
mES[GLI2] cells (Fig. 2) follows the same pattern of
Tbx5 upregulation seen in differentiating P19[GLI2] cells
[33]. When HH signalling is inhibited in P19 EC or mES
cells by KAAD-cyclopamine, Tbx5 expression is reduced
(Figs. 4 and 5e), similarly to P19 EC cells overexpressing
dominant-negative GLI/EnR [33]. Interestingly, Tbx5 is
expressed in SHF cells that receive HH signals in vivo,
Fig. 6 A model summarizing the role of the HH signalling pathway and its primary transducer, GLI2, during mES cell cardiomyogenesis. a In this
study, GLI2 expression was observed to positively regulate cardiac progenitor-enriched genes in mES cells (highlighted in green). The solid black
arrows indicate HH/GLI2’s proposed direct regulation. The hollow green arrow marks the transition that is enhanced by GLI2. b GLI2-regulated
enrichment of cardiac progenitor transcripts may be explained in part by the ability of the transcriptional activator form of GLI2 (GLI2A) (light green
ellipses, B) - mediated via a functional HH signalling pathway (light blue ellipses) - to enrich BRG1 association at GLI2-specific Mef2c site C. This
enrichment site is proximal to known SHF enhancer regions (I,II). Other cofactors (dash-outlined ellipses), including the remaining BAF complex
members and other unidentified SHF-related transcription factors (?) may support this GLI2-mediated association. c When KAAD-cyclopamine
inhibits HH signalling, GLI2 is likely degraded, which leads to a reduction of BRG1 association on Mef2c site C. Although we have not observed
the formation of GLI2R in our system (data not shown), it is possible that GLI2 may be processed into GLI2R (orange truncated ellipses, C) when
HH signalling is blocked [13]. Also, GLI3R (included in the orange truncated ellipses, C) may contribute to the repression of Mef2c expression.
The downstream binding of either GLI2R or GLI3R to Mef2c has yet to be assessed ( )
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and a TBX5-HH network is required for atrial septation
[87]. Although the regulation of Tbx5 expression by the
HH pathway is yet to be determined in vivo, based on
results from previous reports and our observations,
Tbx5 expression is regulated by HH signalling in vitro,
during P19 EC and mES cell differentiation.
In contrast to Mef2c, Nkx2-5, and Tbx5 upregulation
in mES[GLI2] cells, Gata-4 expression is not affected
when GLI2 is overexpressed (Fig. 2). Importantly, Gata-
4 transcript levels were downregulated in mES cells
treated with cyclopamine (Fig. 4), similarly to P19 EC
cells (Fig. 5e and ref. [32]). This suggests that while
exogenous Gli2 cannot enhance Gata-4 expression in
differentiating mES cells, repression of endogenous HH
signalling is sufficient to reduce its expression. It is pos-
sible that Gata-4 induction is more efficient with other
Gli family members, that Gata-4 responds to Hh signal-
ing with a different kinetic, or that it responds at a dif-
ferent threshold of Hh-Gli activity, compared to the
other cardiac transcription factor genes. Previous studies
have shown that Gata-4 expression might be independ-
ently regulated from Mef2c, Nkx2-5, and/or Tbx5 ex-
pression [84, 88, 89]. Removal of the adjacent endoderm
from the side of a developing avian heart, or a condi-
tional knockout of Baf250a in the SHF of the developing
murine heart results in decreased Nkx2-5 and Mef2c ex-
pression while Gata-4 levels remain unaffected [84, 88].
In mES cells, overexpression of the cardiac progenitor
gene regulator, Yin Yang 1 (YY1) enhances Nkx2-5 and
Tbx5 expression with no apparent effect on Gata-4 ex-
pression [89]. Therefore, our observation of Mef2c,
Nkx2-5, and Tbx5 upregulation in mES[GLI2] cells with
no observable effect on day 6 Gata-4 expression is in
line with previous studies and could provide insight into
a Gli2-dependent and independent regulation of mES
cell cardiomyogenesis.
In summary, the activation or suppression of the HH
signaling in mES cells yields a concerted up- or down-
regulation of multiple cardiac progenitor transcription
factor genes. Since our experiments were carried out
using total cell populations, we cannot rule out the pos-
sibility that this occurred in a disorganized manner, with
individual cells upregulating only one of the multiple
cardiac progenitor specific genes we saw induced at the
population level. Previous work by our and other labs, as
well as this work, demonstrate that the induction pat-
terns of Nkx2-5, Tbx5, MEF2C and Gata-4 in differenti-
ating mES and P19 cells mimic each other, ultimately
culminating in maximal transcription on the same days
of differentiation, just before or on the onset of the ex-
pression of structural cardiac muscle genes (Fig. 2, and
[27–29, 32, 33, 45]). Moreover, simultaneous expression
of Gata-4 and Tbx5 is detected in hES-derived cardio-
vascular progenitors and cardiomyocytes, but not in
smooth muscle or endothelial cells [90]. These reports
suggest that the expression of multiple signature cardiac
muscle progenitor genes represents an induction of car-
diac muscle progenitors and differentiated cardiomyo-
cytes. Therefore, we deem unlikely the possibility of
illegitimate expression of the overall signature cardiac
progenitor specific genes in other cell types. Neverthe-
less, a transcriptome analysis at a single-cell level or
after enrichment using cell surface markers specific for
cardiac progenitors would help to directly address this
question by providing an estimate of cell heterogeneity
in the cultures.
Modulation of HH signalling does not alter the number of
mES cardiomyocytes
Although modulation of HH signalling through Gli2
overexpression or application of cyclopamine regulates
Nkx2-5, Mef2c and Tbx5 cardiac progenitor gene expres-
sion in mES cells (Figs. 2 and 4), this does not alter the
percentage of cardiomyocytes (Figs. 3 and 4). One ex-
planation might lie in Gata-4 expression. Namely,
Gata-4 appears to be a limiting factor, in a transcrip-
tion factor cocktail, to induce MyHC expression in
mES cells [91]. Therefore, the lack of Gata-4 enhance-
ment by exogenous GLI2 may offer an explanation for
the lack of cardiomyocyte number increase in mES[-
GLI2] cultures. HH signalling gain-of-function experi-
ments in P19 cells showed both an induction and
enhancement of cardiomyogenesis [31, 33]. P19 cells
may be more susceptible to differentiate into cardio-
myocytes as they are more prone to differentiate into
cells of the mesodermal lineage [35]. In contrast, mES
cells differentiating through EBs in the absence of any
other external stimuli give rise to cell types from all
three germ layers [76, 92, 93] and thus may not have as
many mesoderm cells that are susceptible to HH-
mediated regulation. It is possible that GLI2 overex-
pression affects the differentiation of other cell types as
HH signalling regulates many developmental programs
in vivo [14, 65, 66], resulting in a lower percentage of
cardiomyocytes in mES[GLI2] cultures. Another possi-
bility is that there may be other additional factors,
mechanisms and signalling pathways in mES cells that
regulate the transition of pre-cardiac mesoderm to car-
diomyocyte progenitor cell when compared to P19 EC
cells. Lastly, HH signalling may enhance mechanisms in
the neighbouring lineages that in turn negatively regulate
cardiac differentiation in mES cells.
GLI2 immunoprecipitates with BRG1 during mES
cardiomyogenesis and active HH signalling regulates
BRG1 association with Mef2c gene
To determine the mechanism of Gli2 during in vitro car-
diomyogenesis, we used both mES(Gli2) and P19(Gli2)
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differentiating cells. The co-immunoprecipitation of GLI2
and BRG1 in differentiating mES cells (Fig. 5a) is in agree-
ment with previous observations of HA-tagged GLI2
immunoprecipitation with BRG1 in NIH 3 T3 cells
[42]. To investigate the significance of this interaction,
we tested the hypothesis that GLI2 and BRG1 co-
regulate cardiomyogenesis in vitro by modulating the
expression of GLI2 target genes. In this light, we fo-
cused on Mef2c gene, a direct target of GLI2 during
P19 EC cell cardiomyogenesis [33]. Increased Mef2c
transcript levels in mES[GLI2] (Fig. 2) support and ex-
tend these results. Moreover, BRG1 associates with the
first exon in the Mef2c gene [84], where other proteins,
including MyoD, are known to bind [94], but which
lacks GLI consensus binding site (Fig. 5b).
The anti-BRG1 ChIP analysis from day 4 differentiat-
ing P19 EC control cells demonstrates that BRG1 associ-
ates with Mef2c sites C, D, and G-I (Fig. 5c), which GLI2
has been shown to bind under similar conditions [33].
These results support and extend a previous report [84]
by showing that BRG1 can associate with GLI2-specific
Mef2c sites C and D, which are closer to the ISL-1-
dependent and NKX2-5/FOXH1-dependent SHF enhan-
cer regions than sites previously identified (Fig. 5b) [84].
Of these two sites, Brg1 is more efficiently recruited to
Mef2c site C in P19 cells overexpressing Gli2. Moreover,
when HH signalling in P19 cells is blocked, there is a re-
duction of Brg1 association with this site. Thus, our
findings indicate that BRG1 is recruited to at least one
Mef2c gene regulatory element in a HH- and GLI2-
dependent manner.
Our hypothesis that Gli2 and Brg1 may share common
chromatin targets is also supported by the identification
of additional 1892 putative GLI- and BRG1-target genes
through an in silico analysis (Additional file 5: Table S1),
where BRG1 genome-wide ChIP-sequencing peaks from
[57] were screened for conserved GLI consensus binding
motifs. While we did not identify Mef2c as a common pu-
tative target, most probably due to the stringent condi-
tions of the analysis, we did identify previously reported
shared GLI- and BRG1-target genes, Gli1 and Ptch1 [42],
amongst the theoretical targets, validating this bioinfor-
matic assay (Additional file 5: Table S1).
A gene ontology analysis identified a broad spectrum
of biological processes that are significantly enriched
for these genes, such as regulation of gene expression,
cell differentiation and system development (Table 4).
As GLI2 and BRG1 are ubiquitously expressed proteins
[57, 95], it is possible that they might co-regulate a variety
of cellular and developmental programs. Notably, we iden-
tified nervous system development, where GLI2 and
BRG1 are known to interact [42], and heart development
(Table 4). Foxh1, Tbx20, Notch1, and Wnt5a are amongst
the potential targets in the heart development category.
Foxh1 and Tbx20 are expressed in the SHF field, while
Notch and Wnt signalling pathways are known to regulate
heart development [5]. Thus, GLI2 and BRG1 may co-
regulate cardiac genes that have yet to be identified. More-
over, we predict that this co-regulation may be common
to other developmental programs, which is supported by
the identification of additional HH-dependent GO cat-
egories, such as osteoblast differentiation, nervous system
development and cell cycle regulation [66].
Conclusion
Taken together, our results indicate that GLI2 and BRG1
co-operate to regulate cardiomyogenesis in vitro. We
propose a mechanism where HH signaling, through acti-
vated GLI2, recruits BRG1 along with other potential co-
factors to the Mef2c gene site C to promote Mef2c expres-
sion (Fig. 6b). Inhibition of HH signaling results in re-
duced BRG1 association at Mef2c site C and reduced
Mef2c expression (Fig. 6c). Since BRG1 association corre-
lates with chromatin accessibility [84], we predict that
GLI2 might recruit BRG1 to increase chromatin accessi-
bility on Mef2c and other potential yet unidentified target
genes to regulate in vitro cardiomyogenesis.
Table 4 Selected gene ontology biological processes
significantly enriched among genes within 50 kb of a
BRG1- associating site and GLI consensus binding motifa




501 3.35E-25 Atf2, Meis1, Ncoa2,
Ncor1, Smad2




418 1.04E-22 Angpt1, Fgf15, Fgf18,
Pdgfa








77 4.21E-10 Hoxa2, Hoxa9, Hoxd3,
Yy1
Ear morphogenesis 25 3.67E-09 Atoh1, Otx1, Otx2,
Gata2








20 7.13E-06 Bmp2, Gli1, Gli2




108 4.83E-05 Hdac3, Mll3, Myst2,
Smarca2, Smarcd1
aA complete list can be found in Additional file 5: Table S1
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Additional files
Additional file 1: Figure S1. mRNA expression levels of the Gli2S662A-
Flag transgene in mESC clones stably transfected with a Gli2 expression
plasmid or with the empty vector. Total RNA was extracted from cells at
various time points during differentiation. Expression values are relative
to those at day 0 with the clone “mESC[Flag]#1” and are normalized to
β-actin. For each clone, n = 1. (PDF 367 kb)
Additional file 2: Figure S2. GLI2 may regulate early neurogenesis
during mES cell differentiation. Total RNA was isolated from differentiating
mES[GLI2] and mES[Ctrl] cultures on days indicated and analyzed using
qPCR for the expression of (A) Pax3 and (B) Ascl1. Expression levels were
normalized to β-actin, calibrated to day 0 mES[Ctrl] culture expression levels,
and presented as a percentage of the highest expression level recorded, per
gene. Error bars represent +/- SEM; n = 3. One-tailed Student’s T-tests were
used for statistical analyses. Grey lines represent paired T-tests; black lines
represent unpaired T-tests; (star symbol) p < 0.05. (PDF 340 kb)
Additional file 3: Figure S3. Modulation of HH signalling does not
affect cell proliferation or survival. (A) Day 7 cells were treated with EdU
for 1 h prior to staining. At least 5000 cells per sample, across 20 fields of
view, were counted. Error bars represent +/- SEM. Student T-tests were
used for statistical analyses. n = 3. (B) The yields of total RNA extracted
from mES[Ctrl] and mES[GLI2] are given as a proxy for cell numbers in
the cultures. For each time point, n is between 3 and 6, and error bars
represent +/- SEM. (C) The proportion of cells with highly condensed,
apoptotic nuclei after Hoechst staining at day 7 is given. At least 2500
cells per condition per replicate were counted. n = 2. (D) Yields of RNA in
mES cultures treated with methanol vehicle or KAAD-cyclopamine. For each
time point, n = 3, and error bars represent +/- SEM. (E) The proportion of
cells with highly condensed, apoptotic nuclei is given for vehicle- and
KAAD-cyclopamine-treated mES cultures at day 7. n = 2, and at least 500
cells per replicate and condition were counted. (PDF 415 kb)
Additional file 4: Figure S4. Expression of Brg1 in mES and P19 cells
overexpressing Gli2. qPCR analysis of Brg1 mRNA expression levels in (A)
mES[Ctrl] (white bars) and mES[GLI2] (grey bars) cells, or (B) P19[Ctrl]
(white bars) and P19[GLI2] (grey bars) cells. For (A-B) expression levels
were normalized to β-actin, calibrated to day 0 mES[Ctrl] or P19[Ctrl]
culture expression levels, and presented as a percentage of the highest
expression level recorded, per gene. Two-tailed Student’s T-tests were
used for the mRNA statistical analyses; n = 3. (PDF 341 kb)
Additional file 5: Table S1. A complete list of gene ontology biological
processes significantly enriched among genes within 50 kb of a BRG1-
associating site and GLI consensus binding motif. (XLSX 490 kb)
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